Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

  • Wendell Lim
  • Courtesy of UCSF
  • Rewriting Life

    Genetic Programmers Are the Next Startup Millionaires

    The big-ticket acquisition of genetic design company Cell Design Labs signals a coming wave of precision cures.

    A two-year-old company developing molecular “logic” for cancer treatment has been snapped up for $175 million by Gilead Sciences amid a surge of interest in ways to battle disease using engineered immune cells.

    The pricey acquisition of Cell Design Labs, a startup that’s produced no drugs, signals an ongoing acquisition frenzy around one of cancer medicine’s most promising approaches.

    Cell Design Labs, founded by University of California, San Francisco, synthetic biologist Wendell Lim, creates “programs” to install inside T cells, the killer cells of the immune system, giving them new abilities.

    Sign up for Weekend Reads
    Our guide to stories in the archives that put technology in perspective.
    Manage your newsletter preferences

    Beginning in August, the U.S. approved two novel treatments in which a person’s T cells are genetically reprogrammed to seek and destroy cancer cells.

    Known as “CAR-T,” the treatments are both revolutionary and hugely expensive. A single dose is priced at around $500,000 but often results in a cure. Gilead quickly paid $12 billion to acquire Kite Pharma, maker of one of those treatments.

    The initial T cell treatments, however, work only with blood cancers. Now, by picking up Lim’s company, Gilead is investing in the next generation of cell designs that could help treat more types of cancer.

    Going after tumors of the brain, lung, or liver is going to require more precision to kill cancer cells without destroying those vital organs.

    “The first wave of these cell therapies, the miracle was that something worked at all,” says Lim. “In the future it will be much more of an engineering discipline. These cells are programmable, so having the right operating system and right language are critical to reaching the next level of sophistication and predictability.”

    Cell Design Labs, which claims to control key patents covering designer T cells, had been developing new designs, including one featuring a molecular dial that let them turn the killing activity of T cells up or down. Another featured a T cell reengineered to turn on only if it is attached to not one but two separate molecules on a target cell. That feature could be helpful in safely hitting harder-to-reach tumors.

    In many ways, Lim says, he got “lucky” in becoming one of the first to pair synthetic biology with immune cells.

    Six years ago, he says, he was still fooling around with yeast and neurons, using his training to make them do interesting tricks by adding new functions.

    But his thinking changed after a meeting with Carl June of the University of Pennsylvania medical school, the doctor famous for early efforts to show that T cell treatments could save leukemia patients.

    “Then it dawned on me that the ability to reengineer immune cells was going to matter,” Lim recalls. “It was like a scene from The Graduate.” Except instead of plastics, June wanted him to remember that the immune system could be the perfect setting for his ideas.

    Gilead will pay up to $567 million in total if things go well with the technology, showing just how vital genetic programming techniques will be in taking the therapies to the next level of sophistication.

    The ability to design T cells with precision also means companies will probably be able to go beyond cancer, turning them into drug delivery drones, letting them hunt HIV, or maybe using them to solve autoimmune diseases (see “10 Breakthrough Technologies 2016: Immune Engineering”).

    Tech Obsessive?
    Become an Insider to get the story behind the story — and before anyone else.

    Subscribe today
    More from Rewriting Life

    Reprogramming our bodies to make us healthier.

    Want more award-winning journalism? Subscribe and become an Insider.
    • Insider Plus {! insider.prices.plus !}* Best Value

      {! insider.display.menuOptionsLabel !}

      Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

      See details+

      What's Included

      Unlimited 24/7 access to MIT Technology Review’s website

      The Download: our daily newsletter of what's important in technology and innovation

      Bimonthly print magazine (6 issues per year)

      Bimonthly digital/PDF edition

      Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

      Special interest publications

      Discount to MIT Technology Review events

      Special discounts to select partner offerings

      Ad-free web experience

    • Insider Basic {! insider.prices.basic !}*

      {! insider.display.menuOptionsLabel !}

      Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

      See details+

      What's Included

      Unlimited 24/7 access to MIT Technology Review’s website

      The Download: our daily newsletter of what's important in technology and innovation

      Bimonthly print magazine (6 issues per year)

    • Insider Online Only {! insider.prices.online !}*

      {! insider.display.menuOptionsLabel !}

      Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

      See details+

      What's Included

      Unlimited 24/7 access to MIT Technology Review’s website

      The Download: our daily newsletter of what's important in technology and innovation

    /3
    You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.